Government Approves Skymap Pharmaceuticals’ ₹121 Crore Bid for IMPCL Strategic Sale

The Government of India has approved the strategic sale of Indian Medicines Pharmaceutical Corporation Ltd (IMPCL) to Skymap Pharmaceuticals Pvt Ltd for more than ₹121 crore. 

The transaction involves the transfer of the government’s entire equity stake along with management control in the Ayurvedic and Unani medicines manufacturer. The disinvestment process was carried out through a competitive bidding mechanism overseen by multiple government bodies.

Government Clears IMPCL Strategic Sale

The Finance Ministry announced that Skymap Pharmaceuticals Pvt Ltd emerged as the successful bidder for acquiring 100% stake in IMPCL.

According to the ministry, the company submitted the highest financial bid of ₹121 crore, which was above the reserve price set for the transaction. Two financial bids were received as part of the final stage of the strategic disinvestment process.

The sale also includes the transfer of management control of IMPCL to the successful bidder.

About IMPCL

Indian Medicines Pharmaceutical Corporation Ltd operates under the Ministry of Ayush and is involved in the manufacturing and supply of standardised Ayurvedic and Unani medicines.

The company has been engaged in producing traditional medicine formulations and supplying them through government-supported healthcare and wellness channels.

The Cabinet Committee on Economic Affairs (CCEA) had granted in-principle approval for the strategic disinvestment of IMPCL in November 2017.

Bidding and Disinvestment Process

The government stated that the transaction was conducted through a two-stage open and competitive bidding process.

The process involved consultations and approvals from several government bodies, including an inter-ministerial group, the core group of secretaries on disinvestment, and the empowered alternative mechanism.

In September 2023, the government had issued a Preliminary Information Memorandum (PIM), inviting expressions of interest from potential bidders for the sale of IMPCL.

A total of seven interested parties had submitted expressions of interest, all of whom were shortlisted as qualified bidders for the next stage of the process.

Letter of Award Issued

The Finance Ministry confirmed that the Letter of Award has been issued to Skymap Pharmaceuticals Pvt Ltd.

The ministry also stated that the Secretary of the Department of Investment and Public Asset Management (DIPAM) and the Secretary of the Ministry of Ayush have been authorised to complete and close the transaction at the earliest.

Read More: RBI Dollar-Rupee Swap Attracts Strong Demand with Nearly $10 Billion Bids.

Want to track these market movements in Hindi? Visit Angel One News for daily updates and comprehensive share market news in Hindi.

Conclusion

The approval of the strategic sale marks another step in the government’s disinvestment programme involving public sector entities. With the transaction moving towards completion, market participants and stakeholders may monitor how the ownership transition impacts IMPCL’s operations and future business direction.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.